Document is current
Any future updates will be listed below
-
Authors
Yanes, M. I. Luis https://orcid.org/0000-0003-4580-0127
Diaz-Curiel, M.
Peris, P.
Vicente, C.
Marin, S.
Ramon-Krauel, M.
Hernandez, J.
Broseta, J. J.
Espinosa, L.
Mendizabal, S.
Perez-Sukia, L.
Martínez, V.
Palazón, C.
Piñero, J. A.
Calleja, M. A.
Espin, J.
Arborio-Pinel, R.
Ariceta, G.
- License Information
-
More Information
Article History
Received: 1 March 2022
Accepted: 17 July 2022
First Online: 29 July 2022
Declarations
:
: This study was approved and classified by the Spanish Agency for Medicines and Health Products (AEMPS) as a non-interventional observational post-authorization study and was approved by an Ethics Committees for Clinical Research (CEIC; University Hospital Puerta de Hierro Majadahonda) (Approval No. 18.17). Furthermore, this study has been performed in accordance with the Declaration of Helsinki.
: Patients aged 12–18 years, adult patients, and caregivers or parents of all pediatric patients were informed verbally and in writing, and informed consent was obtained before participation in the study.
: Not applicable.
: MILY, PP, CV, MR-K, JH, LE, SM, LP-S, VM, CP, JAP, MAC and JE have received lecture fees from Kyowa Kirin Farmacéutica S.L. SM and JJB have received lecture fees and advisory honoraria from Kyowa Kirin Farmacéutica S.L. GA has received lecture fees and advisory honoraria from Kyowa Kirin Farmacéutica S.L. as well as support to attend scientific meetings. MD-C declares that he has no competing interests.
